• Consideration of age alone is generally inadequate. Interindividual variability in comprehension and willingness/motivation to respond also should be assessed.
Epidermolysis Bullosa-A Rare Disease
• Epidermolysis bullosa (EB) is a family of genetic skin fragility disorders, clinically characterized by blistering of the skin in response to friction or minor trauma.
5
• Widespread, recurrent wounds in patients with generalized EB caused by skin blistering can lead to disfigurement, disability, and premature death in early adulthood, mainly from a particularly aggressive form of cutaneous squamous cell carcinoma.
6
• EB is extremely rare, with an estimated prevalence (all subtypes) of 0.10 to 0.60 cases per 10,000 population in the European Union. In the United States, 1 out of every 50,000 live births is affected by EB.
7
• There is no cure for EB. The current standard of care for EB is supportive; palliative wound care consists of changing dressings and monitoring the wound site for excessive exudate and/or infection.
Health-Related Quality-of-Life Issues in Epidermolysis Bullosa
• Published literature highlights the following important health-related quality-of-life (HRQOL) issues specific to patients with EB 5, [8] [9] [10] [11] [12] [13] [14] [15] :
-Limitations in physical functioning (e.g., impact of pain or itch on sleeping, eating, writing, bathing/showering, moving around inside and outside the house, shopping, playing sports) -Emotional, social, and psychological effects (e.g., frustration, embarrassment, anxiety, depression, teasing/staring, relationships with friends and family)
-Aspects specific to wound treatment (e.g., pain during wound dressing changes).
OBJECTIVE
• To identify and evaluate HRQOL measures for use with a pediatric population (aged 3 to < 18 years) with EB.
METHODS
• A structured PubMed search was conducted using Medical Subject Heading search terms.
• Of the 143 abstracts identified, 40 were appropriate for further evaluation; 33 articles underwent full-text review.
• The following measurement properties were evaluated for each HRQOL measure based on standard criteria 16, 17 : -Practicality
• Availability of age-appropriate version(s)
• Number of items (i.e., respondent burden)
• Recall period -Content validity
• Relevant content for patients with EB
• Age relevance of concepts addressed -Psychometric properties
• Validity (known groups, construct)
• Reliability (test-retest, internal consistency) established in EB population -Use in previous EB studies -Responsiveness to change in EB clinical trials
RESULTS
The review identified 8 HRQOL measures implemented in studies with patients with EB ( Table 1) . 
Summary of Key Measurement Properties

DISCUSSION
• 8 HRQOL measures were identified and reviewed. As expected, no single HRQOL measure covers the full experience of EB across the age spectrum of pediatric patients.
• The EQ-5DY, a generic measure of HRQOL, may potentially be used to compare the burden of EB in pediatric patients aged 8 to 15 years with the burden of other pediatric illnesses.
• The CDLQI covers the greatest portion of the age range of interest (4-16 years); this measure also is available in two different child-friendly formats for administration (cartoon and text); however, it lacks content validity in patients with EB.
• The QOLEB was the only instrument for which content was derived from and psychometric properties were established in patients with EB.
• The QOLEB items focus on emotional and functional HRQOL domains. Despite pediatric input during development:
-Not all QOLEB content is relevant to children/adolescents:
• Item #12: Have you needed to, or do you need to, modify your home (installing ramps, etc.) due to your EB?
• Item #15: How are you or your family affected financially by your EB?
-Age-appropriate versions are not available. During the development and validation of this questionnaire:
• Children younger than 10 years included their parents' advice when completing the questionnaire.
• Children who were unable to read or who were younger than 8 years had their parents complete the questionnaire.
LIMITATIONS
• Parental concerns were not evaluated in this study.
CONCLUSIONS
• EB is an extremely rare disease that has a profound impact on patients' HRQOL.
• The rarity of EB makes assessment of HRQOL challenging and creates practical difficulties for the following activities:
-Developing new disease-specific questionnaires (e.g., limited number of patients available for concept elicitation and psychometric testing)
-Testing of existing HRQOL questionnaires (e.g., limited number of patients available for assessing content validity)
-Developing new language versions of measures (i.e., limited number of patients available for linguistic validation).
• An HRQOL instrument that evaluates age-appropriate concepts for EB was not identified. Content validity was lacking in the majority of measures evaluated.
• The broad age range of patients with EB, from young children to adolescents and young adults, means that a single measure is unlikely to be suitable for all patients.
-The impact of EB will vary by age, consistent with normal childhood growth and development. Thus, instrument content also may need to vary by age group.
-Appropriate format, question structure, and mode of completion for HRQOL measures also will vary by age.
